Clinical Trial Update: Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating a stabilized RSV F subunit vaccine with or without alum, focusing on dose, safety, tolerability, and immunogenicity in healthy a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Disease

Drugs mentioned

• DS-Cav1 RSV F subunit vaccine (VRC-RSVRGP084-00-VP) (RSV F subunit vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Respiratory Syncytial Virus | Phase 1 | Status: COMPLETED | Results posted: 2020-10-23